Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging

NCT07403825 is registered in ClinicalTrials.gov with Biobizkaia Health Research Institute as lead sponsor.

NCT NCT07403825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07403825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging
Lead sponsor
Biobizkaia Health Research Institute
Phase
Phase 4
Overall status
Recruiting
Start date
May 25, 2026
Completion date
October 31, 2028
Enrollment
100 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration, age related